



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

ESC 2015 Publication Schedule / Conference Call Details

Ladies and Gentlemen,

Findings from the Phase IIb ARTS HF study evaluating Finerenone versus Eplerenone in patients with worsening chronic heart failure with type 2 diabetes and/or chronic kidney disease will be presented in a Hot Line Session at the European Society of Cardiology (ESC) congress in London on August 31, 2015 from 11:00 a.m. – 12:30 p.m. BST (12:00 noon – 01:30 p.m. CEST).

We cordially invite investors and analysts to participate in our conference call on this occasion.

The schedule is as follows:

Monday August 31, 2015	Internet address for all information material and webcast: www.investor.bayer.com / www.investor.bayer.de
	Press release on Finerenone
02:00 p.m. CEST	Investor Conference Call to discuss findings from the ARTS HF Phase IIb study of Finerenone presented at ESC with Dr. Joerg Moeller, Head of Global Development at Bayer HealthCare Dr. Frank Misselwitz, Head of Global Clinical Development Cardiovascular Dr. Alexander Rosar, Head of Investor Relations
	Dial-in Numbers International: +44 203 059 5869 UK: 0203 059 5869 US: 1 855 272 3513 Germany: 069 566 036 000 If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until September 3, 2015. A live audio broadcast (English only) will be available on the internet.
	Replay Dial-in Numbers International: +44 121 260 4861, Pin 154253# UK: 0121 260 4861, Pin 154253# US: 1 724 5589 653, Pin 154253# Germany: 069 710 488 70, Pin 154253#
06:00 p.m. CEST	On-demand version of the conference call webcast available on the internet. A transcript of the call will be available on the Internet as soon as possible.

CEST = Central European Summer Time = Universal Time Coordinated (UTC) + 2 hours

BST = British Summer Time = CEST – 1 hour

Best regards,
Bayer Investor Relations